Approval · Notice of Compliance 25539 · 2021
BASAGLAR: Notice of Compliance 25539
Issued March 26, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25539
- Date
- March 26, 2021
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BASAGLAR | Not yet assigned | — |
Medicinal ingredients
- INSULIN GLARGINE 100 UNIT per ML
- INSULIN GLARGINE 100 UNIT per PEN